Joining forces to improve wellbeing
Joint Funding Panel
A panel of recognised experts from a wide range of fields has been appointed to support the delivery of the HIC Fund Programme.
The Joint Funding Panel composition
William M. Burns
Mr Burns has had a long and distinguished career in the global pharmaceuticals industry, having worked for many years for Roche; most recently as Chief Executive Officer of their Pharmaceuticals Division and as a member of the Roche Group Corporate Executive Committee. He has extensive experience of international pharmaceuticals and of mergers and acquisitions. Among his many achievements during his time with Roche, he had significant involvement in the acquisition and privatisation of Genentech, he led the integration of Boehringer Mannheim Therapeutics and he played a lead role in the negotiations resulting in Roche becoming a majority owner of Chugai in Japan. He retired from Roche in January 2010, but was recently appointed to be a member of the board of Roche Holdings, and continues to sit on the boards of Chugai Pharmaceutical and Genentech Inc. Dr Burns also served for Beecham Pharmaceuticals from 1969.He spent the next 17 years with Beecham in a variety of roles of increasing responsibility, based in the UK and Japan. He has been a non-executive Director of Shire plc since March 2010. Mr Burns is the Chairman of the Health Innovation Challenge Fund Joint Funding Committee.
Professor Stephen Smye
Director of Research and Development at the Leeds Teaching Hospitals
Deputy Director of the UK Clinical Research Network
Honorary Professor of Medical Physics and Health Research in the Faculty of Medicine, Dentistry and Health at Leeds University
Professor Smye has worked in nuclear medicine and bioengineering, and was Head of Medical Physics and Engineering at the Leeds Teaching Hospitals from 1998 until 2008. He was also President of the Institute of Physics and Engineering in Medicine (2001-2003). His research interests lie in mathematical modelling of physiological processes. He has played a key role in encouraging high quality translational research and innovation, including supporting good working relationships between physical scientists and clinicians at both a local and national level. These collaborations currently entail research programmes in a number of areas including; modelling drug transport in tumours (with Dr Roger Philips, University of Bradford, Professor Brian Sleeman, Department of Applied Mathematics and Dr Pam Jones, Leeds Institute of Molecular Medicine), electroporation (with Professor Peter Olmsted, Physics Department), the development of a novel in-vivo electroporation technique (with Dr Martin Robinson, University of York and Dr Tony Evans, Division of Medical Physics) and measurement and modelling of the gravid uterus electro-hysterograms (with Professor Arun Holden, Faculty of Biological Sciences and Mr Nigel Simpson Faculty of Medicine and Health). Previous work has included modelling the variation of blood gases in ventilated neonates, optimising the delivery of drug aerosols, the development of electrical techniques for the measurement of hydration status, the development and use of mathematical models to measure dialysis efficiency and clot formation, the use of TeraHertz radiation to measure tissue properties and application of neural networks to clinical datasets. Funders include NIHR, EPSRC, Yorkshire Cancer Research, MRC, Leukaemia Research Fund, SPARKS, NHS R&D. He was co-applicant on a recent successful application to the National Institute of Health Research (NIHR) to create a Health Technology Cooperative (Devices for Dignity), led by Professor Wendy Tindale of the Sheffield Teaching Hospitals Foundation Trust.
He has also been involved in the development of NHS policy for Research and Development, and is a member of the NIHR Advisory board and the MHRA Medical Technology Forum. He is also a member of the Royal College of Physician's Standing Committee on Academic Medicine and was made an honorary Fellow of the College in 2005.
Joe Smith, MD, PhD
Chief Medical and Science Officer
West Wireless Health Institute
Dr Smith is Chief Medical and Science Officer of the West Wireless Health Institute in San Diego. He was previously Vice President, Emerging Technologies for Johnson & Johnson in the Corporate Office of Science and Technology. His background includes an undergraduate degree in Electrical Engineering (EE) from Johns Hopkins University, a Master's degree in EE from the Massachusetts Institute of Technology (MIT), a PhD in Medical Engineering and Medical Physics from the Harvard-MIT Division of Health Sciences and Technology, and an MD from Harvard Medical School. He completed his medical internship and residency at Brigham and Women's Hospital in Boston, and completed his cardiology and clinical electrophysiology training at Brigham and Women's hospital, the Krannert Institute of Cardiology in Indianapolis, and Washington University in St. Louis. From 1991 through 2000, he held academic positions at the School of Medicine (Cardiology) and the Department of Biomedical Engineering at Washington University in St. Louis and served as Associate Director of Cardiac Electrophysiology at Barnes Hospital. From there, he went on to found the Arrhythmia Institute in Fairfax Virginia, a center of excellence in clinical cardiac electrophysiology and clinical research. From January 2003 through December of 2006 he served as Senior VP and Chief Medical Officer of Guidant /Boston Scientific - Cardiac Rhythm Management, where he provided senior scientific and medical leadership in research and development, new product planning, clinical trial design and conduct, healthcare and reimbursement policy, and medical education. He joined Johnson & Johnson in 2007 as Vice President, Microelectronic Technologies for Cordis Corporation, a Johnson & Johnson company.
He has published in the areas of cardiac electrophysiology with special interest in ICD technology, catheter ablation, atrial fibrillation, and quantitative analytical techniques in biomedical signal processing, has been a consultant to many companies involved in the advancement of innovative medical technologies, and holds a number of patents in the area of signal processing and catheter and defibrillator design.
Professor Thomas J Walley, MB,BCh, MD, FRCPI, FRCP, CBE
NIHR Evaluation, Trials and Studies and Director of the HTA Programme
Consultant Physician and Professor of Clinical Pharmacology
Tom Walley has been Professor of Clinical Pharmacology at Liverpool University since 1994, also working as a Consultant Physician at the Royal Liverpool University Hospital. He formerly headed a research group at Liverpool University, focusing on drug prescribing, pharmaceutical policy, and clinical effectiveness and cost-effectiveness.
Since 2004, he has been on secondment to the NHS, as Director of the National Institute for Health Research (NIHR) Health Technology Assessment programme (info), and in 2008 his role was expanded to Director of Evaluation, Trials and Studies.
He was awarded a CBE in 2008 for services to medicine.
Professor Walley's main research interests include prescribing behaviour and pharmaceutical policy, and clinical-effectiveness and cost-effectiveness.
Professor Richard Hobbs
Head of Department, Professor of General Practice
University of Oxford
Richard Hobbs is currently Professor and Head of the Department of Primary Health Care. He is the Director of the NIHR National School for Primary Care Research (2009-) and was co-Director of the Quality and Outcomes (QOF) Review Panel from 2005-09. He sits on several national and international scientific and research funding boards, including the Council of the British Heart Foundation and the Board of the British Primary Care Cardiovascular Society. He currently chairs the Council for Cardiovascular Primary Care, European Society of Cardiology (ESC); the Prevention and Care Board, British Heart Foundation; and the European Primary Care Cardiovascular Society (EPCCS).
Professor Hobbs‘research interests focus on cardiovascular epidemiology and clinical trials, especially relating to vascular and stroke risk, and heart failure. Overall his publications include 28 book chapters, 12 edited books and over 320 original papers in peer reviewed journals such as the Lancet, Annals of Internal Medicine, BMJ, Atherosclerosis, EHJ and Stroke. His research has impacted on international health policies and clinical guidelines. Within the NHS, he has consulted on National Service Frameworks for CHD, atrial fibrillation, and heart failure and several National Institute of Clinical Excellence (NICE) reviews. He has provided clinical care in inner-city general practice for 30 years.
Professor Patrick Maxwell
NIHR Senior Investigator, The Regis Professor of Physic at the University of Cambridge.
Patrick Maxwell has recently moved to the University of Cambridge where he has been appointed as The Regis Professor of Physic. Prior to this new post, he was Professor of Medicine and Director of the Division of Medicine at University College London.
His undergraduate training was at Oxford (1983) and St Thomas's Hospital (MBBS with Distinction 1986). He subsequently trained as a nephrologist, working on the Renal Units at St. Thomas¹ Hospital, the Hammersmith Hospital, Guy¹s Hospital and the Churchill Hospital (Oxford) and completed specialist training in General (Internal) Medicine. He has been an Honorary Consultant since 1996, and was University Lecturer and then Reader in Nephrology at the University of Oxford (from 1996-2002). He was Professor of Nephrology at Imperial College London, Hammersmith Campus (2002-08).
Professor Maxwell started his research into oxygen sensing in Peter Ratcliffe’s group in Oxford in 1991. He has worked since on oxygen sensing and has been involved in a number of important discoveries in this field. The most significant contributions concern the transcription factor Hypoxia-Inducible Factor (HIF), particularly the molecular mechanism by which it is inactivated in the presence of oxygen. With collaborators, he showed that genetic activation of the HIF pathway is a hallmark feature of most kidney cancers and identified mutations in different genes in the HIF pathway that cause erythrocytosis.
With three other scientists he founded ReOx Ltd in 2003. This spinout company from the University of Oxford aims to develop HIF activators as therapeutic agents for anaemia and hypoxia. Patrick Maxwell is a member of the Wellcome Trust's Clinical Fellowships funding committee, the SAB of the Roche Foundation for Anaemia Research, the MMC Programme Board and the NIHR Advisory Board. He is also Registrar of the Academy of Medical Sciences and Chair of the Wellcome Trust’s Physiology and Pharmacology funding panel.
As a Consultant Nephrologist he was closely involved in developing the new West London Renal and Transplant Centre which opened at the Hammersmith Hospital in 2005 and provides all nephrology, dialysis and renal transplantation services for a catchment area of about 3.5 million.
Professor John O’Brien
John O’Brien is Professor of Old Age Psychiatry and has recently moved from the Institute for Ageing and Health at Newcastle University to the Department of Psychiatry at the University of Cambridge. His research interests include the neurobiology of late life depression, the application of neuroimaging to psychiatric disorders in late life and dementia with Lewy bodies. He is interested in improving methods of early diagnosis, particularly in terms of refining diagnostic criteria to try to detect those with different types of dementia at the earliest possible stages. He has lead consultant responsibility for the Newcastle Memory Clinic and he was a member of the UK NICE Dementia Guideline group. He is an IPA and Vas-Cog Board Member and is an editorial panel member for Psychological Medicine and the American Journal of Geriatric Psychiatry. His other roles include Deputy Editor of International Psychogeriatrics, Associate Director for Dementia for the NIHR DeNDRoN research network, Head of the Postgraduate School of Psychiatry in the Northern Deanery and Past President of the International College for Geriatric Psychoneuropharmacology (ICGP). He has published over 250 peer reviewed papers and edited several books.
Professor Mervyn Singer
Mervyn Singer is Professor of Intensive Care Medicine at University College London. His primary research interests are sepsis and multi-organ failure, infection, shock and haemodynamic monitoring. His group has won 12 national and international research awards, and he has gained over £11m in funding, mainly from the NIHR, MRC, the Wellcome Trust and the European Commission. He has recently been involved in the academic development of two novel monitoring devices for assessing tissue perfusion and a new drug for treating septic shock, as well as in several industry collaborations. He developed an oesophageal Doppler haemodynamic monitor that is now in widespread use worldwide, the use of which has been shown in multiple studies to improve outcomes after major surgery and reduce length of stay. He has led on a number of important multi-centre trials in critical care. He has authored various papers and textbooks including the Oxford Handbook of Critical Care, now in its 3rd Edition, and is a Council member of the International Sepsis Forum. He was the first UK intensivist to be awarded Senior Investigator status by the National Institute for Health Research, and to be invited to give plenary lectures at the European and US Intensive Care Congresses.
Dr Gerd Michel
Dr Gerd Michel was until recently Senior Technology Officer at the Foundation of New Innovative Diagnostics (FIND). He obtained his PhD from the University of Heidelberg, where he was head of the Cellular Signal Transduction and Receptor Research laboratory. He then became Head of Immunology Research at the Bieger Laboratories and Laboratory for Clinical Immunology in Munich. Dr Michel spent 18 years with Abbott's diagnostic division, rising to the post of Director of Medical and Scientific Development for EMEA, including responsibility for new technologies. Dr Michel has developed and/or launched 15 commercial in vitro diagnostic assays, contributed to over 160 peer-reviewed articles and is an inventor on nine patents. He holds fellowships from the University of Aarhus, the German Cancer Research Centre, the University of Chicago and the University of Würzburg. He has held a number of advisory posts, including most recently the WHO industrial liaison board on the '5 x 3' AIDS programme and the OECD advisory board on New Medicines/Diagnostics for Neglected Diseases.